Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’ Simcere To Sell Its 35% Stake In Shanghai Celgen

This article was originally published in PharmAsia News

Executive Summary

China’sSimcere Pharmaceutical Group plans to sell its 35% stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for $48 million, exiting a deal signed in 2009.


Related Content

China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts